[1]
|
A. G. Bader, S. Kang, L. Zhao and P. K. Vogt, “Oncogenic PI3K Deregulates Transcription and Translation,” Nature Reviews. Cancer, Vol. 5, No. 12, 2005, pp. 921-929.
|
[2]
|
J. Karar and A. Maity, “PI3K/AKT/mTOR Pathway in Angiogenesis,” Frontiers in Molecular Neuroscience, Vol. 4, 2011, p. 1. http://dx.doi.org/10.3389/fnmol.2011.00051
|
[3]
|
J. R. Testa and A. Bellacosa, “AKT Plays a Central Role in Tumorigenesis,” Proceedings of the National Academy Sciences of the United States of America, Vol. 98, No. 20, 2001, pp. 10983-10985. http://dx.doi.org/10.1073/pnas.211430998
|
[4]
|
N. E. Buroker, X. H. Ning, Z. N. Zhou, K. Li, W.J. Cen, X. F. Wu, W. Z. Zhu, C. R. Scott and S. H. Chen, “AKT3, ANGPTL4, eNOS3, and VEGFA Associations with high Altitude Sickness in Han and Tibetan Chinese at the Qinghai-Tibetan Plateau,” International Journal of Hematology, Vol. 96, No. 2, 2012, pp. 200-213. http://dx.doi.org/10.1007/s12185-012-1117-7
|
[5]
|
N. A. Lavender, E. N. Rogers, S. Yeyeodu, J. Rudd, T. Hu, J. Zhang, G. N. Brock, K. S. Kimbro, J. H. Moore, D. W. Hein and L. C. Kidd, “Interaction among Apoptosis-Associated Sequence Variants and Joint Effects on Aggressive Prostate Cancer,” BMC Medical Genomics, Vol. 5, No. 11, 2012 , p. 1-15. http://dx.doi.org/10.1186/1755-8794-5-11
|
[6]
|
X. Shu, J. Lin, C. G. Wood, N. M. Tannir and X. Wu, “Energy Balance, Polymorphisms in the mTOR Pathway, and Renal Cell Carcinoma Risk,” Journal of the National Cancer Institute, Vol. 105, No. 6, 2013, pp. 424-432. http://dx.doi.org/10.1093/jnci/djt005
|
[7]
|
J. C. Knight, “Functional Implications of Genetic Varia- tion in Non-Coding DNA for Disease Susceptibility and Gene Regulation,” Clinical Science, Vol. 104, No. 5, 2003, pp. 493-501. http://dx.doi.org/10.1042/CS20020304
|
[8]
|
J. C. Knight, “Regulatory Polymorphisms Underlying Complex Disease Traits,” Journal of Molecular Medicine, Vol. 83, No. 2, 2005, pp. 97-109. http://dx.doi.org/10.1007/s00109-004-0603-7
|
[9]
|
X. Wang, D. J. Tomso, X. Liu and D. A. Bell, “Single Nucleotide Polymorphism in Transcriptional Regulatory Regions and Expression of Environmentally Responsive Genes,” Toxicology and Applied Pharmacology, Vol. 207, No. 2, 2005, pp. 84-90. http://dx.doi.org/10.1016/j.taap.2004.09.024
|
[10]
|
X. Wang, D. J. Tomso, B. N. Chorley, H. Y. Cho, V. G. Cheung, S. R. Kleeberger and D. A. Bell, “Identification of Polymorphic Antioxidant Response Elements in the Human Genome,” Human Molecular Genetics, Vol. 16, No. 10, 2007, pp. 1188-1200. http://dx.doi.org/10.1093/hmg/ddm066
|
[11]
|
F. Claessens, G. Verrijdt, E. Schoenmakers, A. Haelens, B. Peeters, G. Verhoeven and W. Rombauts, “Selective DNA Binding by the Androgen Receptor as a Mechanism for Hormone-Specific Gene Regulation,” The Journal of Steroid Biochemistry and Molecular Biology, Vol. 76, No. 1-5, 2001, pp. 23-30. http://dx.doi.org/10.1016/S0960-0760(00)00154-0
|
[12]
|
M. H. Hsu, U. Savas, K. J. Griffin and E. F. Johnson, “Regulation of Human Cytochrome P450 4F2 Expression by Sterol Regulatory Element-Binding Protein and Lovastatin,” Journal of Biological Chemistry, Vol. 282, No. 8, 2007, pp. 5225-5236. http://dx.doi.org/10.1074/jbc.M608176200
|
[13]
|
H. Takai, S. Araki, M. Mezawa, D. S. Kim, X. Li, L. Yang, Z. Li, Z. Wang, Y. Nakayama and Y. Ogata, “AP1 Binding Site Is Another Target of FGF2 Regulation of Bone Sialoprotein Gene Transcription,” Gene, Vol. 410, No. 1, 2008, pp. 97-104. http://dx.doi.org/10.1016/j.gene.2007.11.017
|
[14]
|
N. E. Buroker, J. Y. Huang, J. Barboza, D. R. Ledee, R. J. Eastman Jr., H. Reinecke, X. H. Ning, J. A. Bassuk and M. A. Portman, “The Adaptor-Related Protein Complex 2, Alpha 2 Subunit (AP2α2) Gene Is a Peroxisome Proliferator-Activated Receptor Cardiac Target Gene,” The Protein Journal, Vol. 31, No. 1, 2012, pp. 75-83. http://dx.doi.org/10.1007/s10930-011-9379-0
|
[15]
|
C. N. Huang, S. P. Huang, J. B. Pao, T. C. Hour, T. Y. Chang, Y. H. Lan, T. L. Lu, H. Z. Lee, S. H. Juang, P. P. Wu, C. Y. Huang, C. J. Hsieh and B. Y. Bao, “Genetic Polymorphisms in Oestrogen Receptor-Binding Sites Affect Clinical Outcomes in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy,” Journal of Internal Medicine, Vol. 271, No. 5, 2012, pp. 499-509. http://dx.doi.org/10.1111/j.1365-2796.2011.02449.x
|
[16]
|
C. N. Huang, S. P. Huang, J. B. Pao, T. Y. Chang, Y. H. Lan, T. L. Lu, H. Z. Lee, S. H. Juang, P. P. Wu, Y. S. Pu, C. J. Hsieh and B. Y. Bao, “Genetic Polymorphisms in Androgen Receptor-Binding Sites Predict Survival in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy,” Annals of Oncology: Official Journal of the European Society for Medical Oncology, Vol. 23, No. 3, 2012, pp. 707-713. http://dx.doi.org/10.1093/annonc/mdr264
|
[17]
|
B. Yu, H. Lin, L. Yang, K. Chen, H. Luo, J. Liu, X. Gao, X. Xia and Z. Huang, “Genetic Variation in the Nrf2 Promoter Associates with Defective Spermatogenesis in Humans,” Journal of Molecular Medicine, Vol. 90, No. 11, 2012, pp. 1333-1342. http://dx.doi.org/10.1007/s00109-012-0914-z
|
[18]
|
J. Wu, M. H. Richards, J. Huang, L. Al-Harthi, X. Xu, R. Lin, F. Xie, A. W. Gibson, J. C. Edberg and R. P. Kimberly, “Human FasL Gene Is a Target of β-Catenin/T-Cell Factor Pathway and Complex FasL Haplotypes Alter Promoter Functions,” PLoS ONE, Vol. 6, No. 10, 2011, Article ID: e26143. http://dx.doi.org/10.1371/journal.pone.0026143
|
[19]
|
M. Alam, V. Pravica, A. A. Fryer, C. P. Hawkins and I. V. Hutchinson, “Novel Polymorphism in the Promoter Region of the Human Nerve Growth-Factor Gene,” International Journal of Immunogenetics, Vol. 32, No. 6, 2005, pp. 379-382. http://dx.doi.org/10.1111/j.1744-313X.2005.00541.x
|
[20]
|
J. C. Bryne, E. Valen, M. H. Tang, T. Marstrand, O. Winther, I. da Piedade, A. Krogh, B. Lenhard and A. Sandelin, “JASPAR, the Open Access Database of Transcription Factor-Binding Profiles: New Content and Tools in the 2008 Update,” Nucleic Acids Research, Vol. 36, Suppl. 1, 2008, pp. D102-D106. http://dx.doi.org/10.1093/nar/gkm955
|
[21]
|
A. Sandelin, W. Alkema, P. Engstrom, W. W. Wasserman and B. Lenhard, “JASPAR: An Open-Access Database for Eukaryotic Transcription Factor Binding Profiles,” Nucleic Acids Research, Vol. 32, Suppl. 1, 2004, pp. D91-D94. http://dx.doi.org/10.1093/nar/gkh012
|
[22]
|
A. Sandelin, W. W. Wasserman and B. Lenhard, “Consite: web-Based Prediction of Regulatory Elements Using Cross-Species Comparison,” Nucleic Acids Research, Vol. 32, Suppl. 2, 2004, pp. W249-W252. http://dx.doi.org/10.1093/nar/gkh372
|
[23]
|
E. Pennisi, “The Biology of Genomes. Disease Risk Links to Gene Regulation,” Science, Vol. 332, No. 6033, 2011, p. 1031. http://dx.doi.org/10.1126/science.332.6033.1031
|
[24]
|
V. Kumar, C. Wijmenga and S. Withoff, “From Genome- Wide Association Studies to Disease Mechanisms: Celiac Disease as a Model for Autoimmune Diseases,” Seminars in Immunopathology, Vol. 34, No. 4, 2012, pp. 567-580. http://dx.doi.org/10.1007/s00281-012-0312-1
|
[25]
|
L. A. Hindorff, P. Sethupathy, H. A. Junkins, E. M. Ramos, J. P. Mehta, F. S. Collins and T. A. Manolio, “Potential Etiologic and Functional Implications of Genome-Wide Association Loci for Human Diseases and Traits,” Proceedings of the National Academy Sciences of the United States of America, Vol. 106, No. 23, 2009, pp. 9362-9367. http://dx.doi.org/10.1073/pnas.0903103106
|
[26]
|
V. Kumar, H. J. Westra, J. Karjalainen, D. V. Zhernakova, T. Esko, B. Hrdlickova, R. Almeida, A. Zhernakova, E. Reinmaa, U. Vosa, M. H. Hofker, R. S. Fehrmann, J. Fu, S. Withoff, A. Metspalu, L. Franke and C. Wijmenga, “Human Disease-Associated Genetic Variation Impacts Large Intergenic Non-Coding RNA Expression,” PLoS Genet, Vol. 9, No. 1, 2013, Article ID: e1003201. http://dx.doi.org/10.1371/journal.pgen.1003201
|
[27]
|
B. N. Chorley, X. Wang, M. R. Campbell, G. S. Pittman, M. A. Noureddine and D. A. Bell, “Discovery and Verification of Functional Single Nucleotide Polymorphisms in Regulatory Genomic Regions: Current and Developing Technologies,” Mutation Research, Vol. 659, No. 1-2, 2008, pp. 147-157. http://dx.doi.org/10.1016/j.mrrev.2008.05.001
|
[28]
|
L. Prokunina and M. E. Alarcon-Riquelme, “Regulatory SNPs in Complex Diseases: Their Identification and Functional Validation,” Expert Reviews in Molecular Medicine, Vol. 6, No. 10, 2004, pp. 1-15. http://dx.doi.org/10.1017/S1462399404007690
|
[29]
|
P. R. Buckland, “The Importance and Identification of Regulatory Polymorphisms and Their Mechanisms of Action,” Biochimica et Biophysica Acta, Vol. 1762, No. 1, 2006, pp. 17-28. http://dx.doi.org/10.1016/j.bbadis.2005.10.004
|
[30]
|
W. Sadee, D. Wang, A. C. Papp, J. K. Pinsonneault, R. M. Smith, R. A. Moyer and A. D. Johnson, “Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy,” Clinical Pharmacology and Therapeutics, Vol. 89, No. 3, 2011, pp. 355-365. http://dx.doi.org/10.1038/clpt.2010.314
|
[31]
|
R. Siegel, D. Naishadham and A. Jemal, “Cancer Statistics, 2012,” CA: A Cancer Journal for Clinicians, Vol. 62, No. 1, 2012, pp. 10-29. http://dx.doi.org/10.3322/caac.20138
|
[32]
|
W. H. Chow, S. S. Devesa, J. L. Warren and J. F. Frau- meni Jr., “Rising Incidence of Renal Cell Cancer in the United States,” JAMA, Vol. 281, No. 17, 1999, pp. 1628- 1631. http://dx.doi.org/10.1001/jama.281.17.1628
|
[33]
|
B. Schlehofer, W. Pommer, A. Mellemgaard, J. H. Stew- art, M. McCredie, S. Niwa, P. Lindblad, J. S. Mandel, J. K. McLaughlin and J. Wahrendorf, “International Renal- Cell-Cancer Study. VI. The Role of Medical and Family History,” International Journal of Cancer, Vol. 66, No. 6, 1996, pp. 723-726. http://dx.doi.org/10.1002/(SICI)1097-0215(19960611)66:6<723::AID-IJC2>3.0.CO;2-1
|
[34]
|
J. Clague, J. Lin, A. Cassidy, S. Matin, N. M. Tannir, P. Tamboli, C. G. Wood and X. Wu, “Family History and Risk of Renal Cell Carcinoma: Results from a Case-Control Study and Systematic Meta-Analysis,” Cancer Epide- miology Biomarkers & Prevention, Vol. 18, No. 3, 2009, pp. 801-807. http://dx.doi.org/10.1158/1055-9965.EPI-08-0601
|
[35]
|
M. L. Nickerson, M. B. Warren, J. R. Toro, V. Matrosova, G. Glenn, M. L. Turner, P. Duray, M. Merino, P. Choyke, C. P. Pavlovich, N. Sharma, M. Walther, D. Munroe, R. Hill, E. Maher, C. Greenberg, M. I. Lerman, W. M. Linehan, B. Zbar and L. S. Schmidt, “Mutations in a Novel Gene Lead to Kidney Tumors, Lung Wall Defects, and Benign Tumors of the Hair Follicle in Patients with the Birt-Hogg-Dube Syndrome,” Cancer Cell, Vol. 2, No. 2, 2002, pp. 157-164. http://dx.doi.org/10.1016/S1535-6108(02)00104-6
|
[36]
|
American Cancer Society, “Cancer Facts and Figures,” 2012.
|
[37]
|
M. Yeager, N. Orr, R. B. Hayes, K. B. Jacobs, P. Kraft, S. Wacholder, M. J. Minichiello, P. Fearnhead, K. Yu, N. Chatterjee, Z. Wang, R. Welch, B. J. Staats, E. E. Calle, H. S. Feigelson, M. J. Thun, C. Rodriguez, D. Albanes, J. Virtamo, S. Weinstein, F. R. Schumacher, E. Giovannucci, W. C. Willett, G. Cancel-Tassin, O. Cussenot, A. Valeri, G. L. Andriole, E. P. Gelmann, M. Tucker, D. S. Gerhard, J. F. Fraumeni Jr., R. Hoover, D. J. Hunter, S. J. Chanock and G. Thomas, “Genome-Wide Association Study of Prostate Cancer Identifies a Second Risk Locus at 8q24,” Nature Genetics, Vol. 39, No. 5, 2007, pp. 645-649.
|
[38]
|
J. E. Phillips and V. G. Corces, “CTCF: Master Weaver of the Genome,” Cell, Vol. 137, No. 7, 2009, pp. 1194-1211. http://dx.doi.org/10.1016/j.cell.2009.06.001
|
[39]
|
M. Tang, B. Chen, T. Lin, Z. Li, C. Pardo, C. Pampo, J. Chen, C. L. Lien, L. Wu, L. Ai, H. Wang, K. Yao, S. P. Oh, E. Seto, L. E. Smith, D. W. Siemann, M. P. Kladde, C. L. Cepko and J. Lu, “Restraint of Angiogenesis by Zinc Finger Transcription Factor CTCF-Dependent Chromatin Insulation,” Proceedings of the National Academy Sciences of the United States of America, Vol. 108, No. 37, 2011, pp. 15231-15236. http://dx.doi.org/10.1073/pnas.1104662108
|